In a major move to make its blockbuster treatments more accessible, global pharma giant Novo Nordisk announced that effective January 1, 2027, it will cut the list prices of Wegovy, Ozempic, and Rybelsus by 35%–50%. 

 

The price for Wegovy (2.4 mg injection and 25 mg tablets) will drop to $675—a roughly 50% reduction—while Ozempic (0.5 mg, 1 mg, and 2 mg injections) and Rybelsus (7 mg and 14 mg tablets) will see cuts of about 35%.

 

The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients, private insurers, and public payers navigating the complex US healthcare system.

 

“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices,” said Jamey Millar, executive vice president, US Operations of Novo Nordisk. 

 

“Our actions today answer that call and remove cost barriers so the value of Wegovy® and Ozempic® can be realized by more patients. The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs.”

 

Novo Nordisk emphasized that semaglutide—the active ingredient in Wegovy and Ozempic—remains unmatched in the GLP-1 class. It is FDA-approved for obesity (Wegovy), type 2 diabetes (Ozempic), type 2 diabetes with chronic kidney disease (Ozempic injection), and comorbid cardiovascular disease (both Wegovy and Ozempic).

 

Through the price cuts, Novo Nordisk aims to expand access to its medicines while continuing other initiatives to make them affordable, including direct-to-patient and self-pay programs.